Orphan Drug Strategies and Developmental Trends

As per the recent researches, the orphan drug market is now opening to display trends seen in traditional pharma markets. The numbers of orphan drug approvals have increased in recent years. Both novel agents and new indications serve as the primary drivers of this recent orphan drug growth. The new business model of orphan drugs could offer a cohesive healthcare resolution that enables pharma companies to develop newer areas of therapeutics, analysis, treatment, monitoring, and patient support. Additionally, the development of orphan drugs is faced with some challenges that are unique to rare diseases. In spite of the challenges, creative Competitive Intelligence (CI) strategies can provide an attentive and improved method for the successful development of orphan drugs.

 

  • Orphan drug stimulus
  • Orphan drug approval
  • Orphan drug verses essential medicines
  • Clinical case studies on rare diseases

Related Conference of Orphan Drug Strategies and Developmental Trends

August 19-20, 2020

European Summit on HIV, STD and STIs

Milan, Italy
September 28-29, 2020

13th Global Infections Conference

Singapore
October 5-6, 2020

12th Euro-Global Conference on Infectious Diseases

Vienna, Austria
November 05-06, 2020

9th Asia Pacific STD and Infectious Diseases Congress

Tokyo, Japan
February 15-16, 2021

8th International Congress on Infectious Diseases

London, UK
February 22-23, 2021

4th Global Experts Meeting on Infectious Diseases

Singapore City, Singapore

Orphan Drug Strategies and Developmental Trends Conference Speakers

Recommended Sessions

Related Journals

Are you interested in